

CITATION REPORT

List of articles citing

CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice

DOI: 10.1016/s0002-9440(10)63863-1
American Journal of Pathology, 2003, 162, 691-702.

Source: <https://exaly.com/paper-pdf/35445941/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
277	Helicobacter pylori- inflammation, immunity and vaccines. 2003 , 8 Suppl 1, 31-5		12
276	Correction: Corrigendum: Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)K 2003 , 426, 584-584		10
275	Chemical carcinogens as foreign bodies and some pitfalls regarding cancer immune surveillance. 2003 , 90, 179-207		30
274	Helicobacter pylori. 2003 ,		0
273	NF-kappa B is required within the innate immune system to inhibit microflora-induced colitis and expression of IL-12 p40. 2003 , 171, 1484-92		54
272	Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. 2004 , 64, 962-8		252
271	Gastroenteritis in NF-kappaB-deficient mice is produced with wild-type Campylobacter jejuni but not with C. jejuni lacking cytolethal distending toxin despite persistent colonization with both strains. 2004 , 72, 1116-25		148
270	Hepatic temporal gene expression profiling in Helicobacter hepaticus-infected A/JCr mice. 2004 , 32, 678-93		31
269	Progression of chronic hepatitis and preneoplasia in Helicobacter hepaticus-infected A/JCr mice. 2004 , 32, 668-77		45
268	Intact gram-negative Helicobacter pylori, Helicobacter felis, and Helicobacter hepaticus bacteria activate innate immunity via toll-like receptor 2 but not toll-like receptor 4. 2004 , 72, 6446-54		184
267	Regulatory cells and infectious agents: detentes cordiale and contraire. 2004 , 173, 2211-5		117
266	Inflammation and Cancer. I. Rodent models of infectious gastrointestinal and liver cancer. 2004 , 286, G361-6		104
265	Interleukin-10 in viral diseases and cancer: exiting the labyrinth?. 2004 , 202, 223-36		90
264	A cancer immunosurveillance controversy. 2004 , 5, 3-4; author reply 4-5		50
263	Response to 'A cancer immunosurveillance controversy'. 2004 , 5, 4-5		16
262	Role of Se-dependent glutathione peroxidases in gastrointestinal inflammation and cancer. 2004 , 36, 1481-95		121
261	Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. 2004 , 287, G7-17		897

260	Commensal bacteria, redox stress, and colorectal cancer: mechanisms and models. 2004 , 229, 586-97		174
259	Sporadic colorectal cancer--role of the commensal microbiota. 2005 , 244, 1-7		95
258	Cure of innate intestinal immune pathology by CD4+CD25+ regulatory T cells. 2005 , 97, 189-92		50
257	A novel enterohepatic <i>Helicobacter</i> species 'Helicobacter mastomyrinus' isolated from the liver and intestine of rodents. 2005 , 10, 59-70		52
256	Disruption of the TGF-beta pathway and modeling human cancer in mice. 2005 , 576, 120-31		6
255	Regulatory T cells and the innate immune system. 2005 , 77-91		
254	Regulatory CD4+CD25+ cells reverse imbalances in the T cell pool of bone marrow transplanted TGepsilon26 mice leading to the prevention of colitis. 2005 , 54, 207-14		9
253	Different <i>Helicobacter hepaticus</i> strains with variable genomic content induce various degrees of hepatitis. 2005 , 73, 8449-52		26
252	Cytotoxic distending toxin is essential for <i>Helicobacter hepaticus</i> colonization in outbred Swiss Webster mice. 2005 , 73, 3559-67		92
251	CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. 2005 , 65, 3998-4004		176
250	The therapeutic implications of intratumoral regulatory T cells. 2005 , 11, 8226-9		36
249	NF-kappa B, an inhibitor of microflora-induced colitis. 2005 , 40 Suppl 1, S22-3		1
248	Dual infection with <i>Helicobacter bilis</i> and <i>Helicobacter hepaticus</i> in p-glycoprotein-deficient mdr1a-/- mice results in colitis that progresses to dysplasia. <i>American Journal of Pathology</i> , 2005 , 166, 1793-806	5.8	88
247	Pathogenomics of Gastric and Enterohepatic <i>Helicobacter</i> Species. 2006 , 301-313		
246	Genomics of <i>Helicobacter</i> Species. 2006 , 91-107		
245	TGF-beta as a T cell regulator in colitis and colon cancer. 2006 , 17, 97-106		88
244	Bacteria, inflammation, and colon cancer. <i>World Journal of Gastroenterology</i> , 2006 , 12, 6741-6	5.6	76
243	Colon cancer and the immune system: the role of tumor invading T cells. <i>World Journal of Gastroenterology</i> , 2006 , 12, 7233-8	5.6	70

242	. 2006 ,	59
241	Detection, eradication, and research implications of Helicobacter infections in laboratory rodents. 2006 , 35, 25-7, 30-6	41
240	Regulating the immune response to tumours. 2006 , 58, 948-61	49
239	Regulatory T cells in experimental autoimmune disease. 2006 , 28, 3-16	56
238	Suppression of anti-cancer immunity by regulatory T cells: back to the future. 2006 , 16, 137-49	53
237	Microbial considerations in genetically engineered mouse research. 2006 , 47, 141-55	25
236	Progressive proliferative and dysplastic typhlocolitis in aging syrian hamsters naturally infected with Helicobacter spp.: a spontaneous model of inflammatory bowel disease. 2006 , 43, 2-14	13
235	Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. 2006 , 12, 465-72	441
234	Mutation accumulation in the intestine and colon of mice deficient in two intracellular glutathione peroxidases. 2006 , 66, 9845-51	37
233	Inhibition of Helicobacter hepaticus-induced colitis by IL-10 requires the p50/p105 subunit of NF-kappa B. 2006 , 177, 7332-9	33
232	Helicobacter hepaticus Dps protein plays an important role in protecting DNA from oxidative damage. 2006 , 40, 597-605	21
231	Proinflammatory CD4+ CD45RB(hi) lymphocytes promote mammary and intestinal carcinogenesis in Apc(Min/+) mice. 2006 , 66, 57-61	76
230	Interleukin-23 drives innate and T cell-mediated intestinal inflammation. 2006 , 203, 2473-83	670
229	Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. 2006 , 66, 828-38	191
228	Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. 2006 , 66, 7395-400	150
227	CD4+CD25+ T regulatory cells and TGF-beta in mucosal immune system: the good and the bad. 2007 , 14, 2245-9	23
226	Rapid reversal of interleukin-6-dependent epithelial invasion in a mouse model of microbially induced colon carcinoma. 2007 , 28, 2614-23	55
225	Inhibitory effect of enterohepatic Helicobacter hepaticus on innate immune responses of mouse intestinal epithelial cells. 2007 , 75, 2717-28	35

224	Wild-type and interleukin-10-deficient regulatory T cells reduce effector T-cell-mediated gastroduodenitis in Rag2 ^{-/-} mice, but only wild-type regulatory T cells suppress Helicobacter pylori gastritis. 2007 , 75, 2699-707	42
223	Breast cancer: should gastrointestinal bacteria be on our radar screen?. 2007 , 67, 847-50	51
222	The cross-talk between dendritic and regulatory T cells: good or evil?. 2007 , 82, 781-94	63
221	Enterohepatic Helicobacter species are prevalent in mice from commercial and academic institutions in Asia, Europe, and North America. 2007 , 45, 2166-72	81
220	Tissue homeostasis and cancer. 2007 , 68, 1333-41	8
219	The role of bacterial pathogens in cancer. 2007 , 10, 76-81	74
218	Helicobacter pylori in colorectal neoplasms: is there an aetiological relationship?. 2007 , 5, 51	54
217	Sporadic colorectal cancer: an infectious disease?. 2007 , 132, 797-801	11
216	Helicobacter Infections in Mice. 2007 , 407-435	1
215	The straw that stirs the drink: insight into the pathogenesis of inflammatory bowel disease revealed through the study of microflora-induced inflammation in genetically modified mice. 2007 , 13, 490-500	12
214	Inflammation in prostate carcinogenesis. 2007 , 7, 256-69	1168
213	Helicobacter pylori evolution and phenotypic diversification in a changing host. 2007 , 5, 441-52	272
212	The impact of regulatory T cells on carcinogen-induced sarcogenesis. 2007 , 96, 1849-54	62
211	Bacterial cytolethal distending toxin promotes the development of dysplasia in a model of microbially induced hepatocarcinogenesis. 2007 , 9, 2070-80	121
210	Mast cells in the promotion and limitation of chronic inflammation. 2007 , 217, 304-28	244
209	The adaptive immune response to sporadic cancer. 2007 , 220, 102-12	46
208	The local and systemic T-cell response to Helicobacter pylori in gastric cancer patients is characterised by production of interleukin-10. 2007 , 125, 205-13	25
207	Do autochthonous tumors interfere with effector T cell responses?. 2007 , 17, 267-74	14

206	A cytokine-mediated link between innate immunity, inflammation, and cancer. 2007 , 117, 1175-83	1363
205	Neonatal co-infection with helicobacter species markedly accelerates the development of inflammation-associated colonic neoplasia in IL-10(-/-) mice. 2007 , 12, 598-604	30
204	The inflammatory and immune response to Helicobacter pylori infection. 2007 , 21, 237-59	124
203	Helicobacter hepaticus HHG11 is a pathogenicity island associated with typhlocolitis in B6.129-IL10 tm1Cgn mice. 2008 , 10, 726-33	19
202	Immunohistochemical testing for Helicobacter Pylori existence in neoplasms of the colon. 2008 , 8, 35	32
201	Helicobacter hepaticus promotes azoxymethane-initiated colon tumorigenesis in BALB/c-IL10-deficient mice. 2008 , 122, 832-8	54
200	Naturally occurring regulatory T cells (CD4+, CD25high, FOXP3+) in the antrum and cardia are associated with higher H. pylori colonization and increased gene expression of TGF-beta1. 2008 , 13, 295-303	70
199	Interleukin-2 in the development and control of inflammatory disease. 2008 , 226, 19-28	186
198	The interleukin-23 axis in intestinal inflammation. 2008 , 226, 147-59	141
197	Role of Toll-like receptors in gastrointestinal malignancies. 2008 , 27, 234-43	148
196	Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. 2008 , 222, 287-98	70
195	Positive and negative influences of regulatory T cells on tumour immunity. 2008 , 27, 5886-93	52
194	Immunogenicity and pathogenicity of Helicobacter infections of veterinary animals. 2008 , 122, 191-203	18
193	Helicobacter hepaticus infection promotes colon tumorigenesis in the BALB/c-Rag2(-/-) Apc(Min/+) mouse. 2008 , 76, 2758-66	52
192	c-Rel is essential for the development of innate and T cell-induced colitis. 2008 , 180, 8118-25	32
191	Systematic high-content proteomic analysis reveals substantial immunologic changes in colorectal cancer. 2008 , 68, 880-8	18
190	Cytotoxic-T-lymphocyte-associated antigen 4 blockade abrogates protection by regulatory T cells in a mouse model of microbially induced innate immune-driven colitis. 2008 , 76, 5834-42	29
189	The roles of sPLA2-IIA (Pla2g2a) in cancer of the small and large intestine. 2008 , 13, 4144-74	30

188	Intestinal mucosal inflammation leads to systemic genotoxicity in mice. 2009 , 69, 4827-34		85
187	Nitric oxide and TNF-alpha trigger colonic inflammation and carcinogenesis in Helicobacter hepaticus-infected, Rag2-deficient mice. 2009 , 106, 1027-32		146
186	Polyps wrap mast cells and Treg within tumorigenic tentacles. 2009 , 69, 5619-22		17
185	Revisiting the prognostic value of regulatory T cells in patients with cancer. 2009 , 27, e5-6; author reply e7		33
184	Reply to C. Badoual et al. 2009 , 27, e7-e7		14
183	Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: prognostic impact may depend on type of treatment and stage of disease. 2009 , 45, e167-74		78
182	CD4+ lymphocytes modulate prostate cancer progression in mice. 2009 , 125, 868-78		26
181	Making and circumventing tolerance to cancer. <i>European Journal of Immunology</i> , 2009 , 39, 2345-53	6.1	12
180	Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. 2009 , 58, 449-59		292
179	A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. 2009 , 15, 1016-22		1140
178	Inflammation and cancer. Methods and protocols. Volume 1: Experimental models and practical approaches. Preface. <i>Methods in Molecular Biology</i> , 2009 , 511, v-viii	1.4	2
177	Bacterial infection of Smad3/Rag2 double-null mice with transforming growth factor-beta dysregulation as a model for studying inflammation-associated colon cancer. <i>American Journal of Pathology</i> , 2009 , 174, 317-29	5.8	33
176	Distinct roles of helper T-cell subsets in a systemic autoimmune disease. 2009 , 113, 389-95		49
175	Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. 2010 , 705, 40-59		84
174	Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease. 2010 , 16, 1411-20		105
173	Unifying roles for regulatory T cells and inflammation in cancer. 2010 , 126, 1651-65		60
172	Cancer inflammation and regulatory T cells. 2010 , 127, 768-79		57
171	Experimental Helicobacter marmotae infection in A/J mice causes enterohepatic disease. <i>Journal of Medical Microbiology</i> , 2010 , 59, 1235-1241	3.2	10

170	Persistent infection of rhesus monkeys with 'Helicobacter macacae' and its isolation from an animal with intestinal adenocarcinoma. <i>Journal of Medical Microbiology</i> , 2010 , 59, 961-969	3.2	25
169	Roles for inflammation and regulatory T cells in colon cancer. 2010 , 38, 76-87		86
168	Regulatory T cells in cancer. 2010 , 107, 57-117		272
167	Infectious causes of colorectal cancer. 2010 , 24, 1019-39, x		17
166	Pathogenic and protective roles of MyD88 in leukocytes and epithelial cells in mouse models of inflammatory bowel disease. 2010 , 139, 519-29, 529.e1-2		81
165	Immune infiltration in human cancer: prognostic significance and disease control. 2011 , 344, 1-24		126
164	Mutations in bone marrow-derived stromal stem cells unmask latent malignancy. 2010 , 19, 1153-66		28
163	IFN- γ inhibits gastric carcinogenesis by inducing epithelial cell autophagy and T-cell apoptosis. 2011 , 71, 4247-59		89
162	Intestinal inflammation and cancer. 2011 , 140, 1807-16		735
161	Pathobionts of the gastrointestinal microbiota and inflammatory disease. 2011 , 23, 473-80		277
160	Omega 3 fatty acids supplementation has an ameliorative effect in experimental ulcerative colitis despite increased colonic neutrophil infiltration. 2011 , 103, 511-8		18
159	Dual roles of immune cells and their factors in cancer development and progression. 2011 , 7, 651-8		433
158	Microbial diversity in saliva of oral squamous cell carcinoma. 2011 , 61, 269-77		108
157	Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. 2011 , 60, 909-18		247
156	CD4+ Foxp3+ regulatory T cells suppress T-cell effector functions in a model of T-cell-induced mucosal inflammation. <i>European Journal of Immunology</i> , 2011 , 41, 3455-66	6.1	21
155	The struggle within: microbial influences on colorectal cancer. 2011 , 17, 396-409		91
154	Helicobacter hepaticus infection in mice: models for understanding lower bowel inflammation and cancer. 2011 , 4, 22-30		140
153	Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. 2011 , 108, 15354-9		307

152	Animal models of colitis-associated carcinogenesis. 2011 , 2011, 342637	70
151	Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. 2011 , 12, 1050-8	36
150	Cancer in inflammatory bowel disease: lessons from animal models. 2012 , 28, 327-33	31
149	Identification of a genetic locus controlling bacteria-driven colitis and associated cancer through effects on innate inflammation. 2012 , 209, 1309-24	37
148	Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer. 2012 , 61, 1163-71	99
147	Suppression of Tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis. 2012 , 31, 3679-95	51
146	Chronic epithelial NF- κ B activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation. 2012 , 109, 14007-12	114
145	Infection-induced colitis in mice causes dynamic and tissue-specific changes in stress response and DNA damage leading to colon cancer. 2012 , 109, E1820-9	177
144	IL-1 β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. 2012 , 209, 1595-609	387
143	Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and colorectal cancer. 2012 , 87, 701-30	94
142	Stromal CD4/CD25 positive T-cells are a strong and independent prognostic factor in non-small cell lung cancer patients, especially with adenocarcinomas. 2012 , 76, 445-51	35
141	Serum metabolomics in a Helicobacter hepaticus mouse model of inflammatory bowel disease reveal important changes in the microbiome, serum peptides, and intermediary metabolism. 2012 , 11, 4916-26	45
140	Regulatory T cells in inflammatory bowel diseases and colorectal cancer. <i>World Journal of Gastroenterology</i> , 2012 , 18, 5688-94	5.6 27
139	Reduction of inflammatory hyperplasia in the intestine in colon cancer-prone mice by water-extract of Cistanche deserticola. 2012 , 26, 812-9	22
138	B-cells and IL-4 promote methylcholanthrene-induced carcinogenesis but there is no evidence for a role of T/NKT-cells and their effector molecules (Fas-ligand, TNF- α /perforin). 2012 , 131, 1499-508	23
137	The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. 2012 , 47, 97-106	81
136	The microbiota and inflammatory bowel disease: insights from animal models. 2013 , 24, 102-6	49
135	Chemistry meets biology in colitis-associated carcinogenesis. 2013 , 47, 958-86	30

134	Molecular Genetics of Inflammatory Bowel Disease. 2013 ,		
133	The Role of Bacteria in Cancer Development. 2013 , 5-78		
132	Microbes and inflammation in colorectal cancer. 2013 , 1, 150-7		43
131	The role of gut microbiota in the pathogenesis of colorectal cancer. 2013 , 34, 1285-300		143
130	Implication of indolamine 2,3 dioxygenase in the tolerance toward fetuses, tumors, and allografts. 2013 , 93, 681-7		31
129	Infectious Agents and Cancer. 2013 ,		4
128	Probiotic <i>Lactobacillus reuteri</i> attenuates the stressor-enhanced severity of <i>Citrobacter rodentium</i> infection. 2013 , 81, 3253-63		59
127	Current status of interleukin-10 and regulatory T-cells in cancer. 2013 , 25, 637-45		165
126	Microbial reprogramming inhibits Western diet-associated obesity. <i>PLoS ONE</i> , 2013 , 8, e68596	3.7	116
125	Chemical and cytokine features of innate immunity characterize serum and tissue profiles in inflammatory bowel disease. 2013 , 110, E2332-41		71
124	<i>Helicobacter pylori</i> infection does not promote hepatocellular cancer in a transgenic mouse model of hepatitis C virus pathogenesis. <i>Gut Microbes</i> , 2013 , 4, 577-90	8.8	12
123	Colitis and colon cancer in WASP-deficient mice require <i>Helicobacter</i> species. 2013 , 19, 2041-50		29
122	Characterization of dextran sodium sulfate-induced inflammation and colonic tumorigenesis in <i>Smad3</i> ^{-/-} mice with dysregulated TGF β . <i>PLoS ONE</i> , 2013 , 8, e79182	3.7	28
121	Microbial symbionts accelerate wound healing via the neuropeptide hormone oxytocin. <i>PLoS ONE</i> , 2013 , 8, e78898	3.7	155
120	Unveiling the Intricacies of <i>Helicobacter pylori</i> -Induced Gastric Inflammation: T Helper Cells and Matrix Metalloproteinases at a Crossroad. 2013 ,		3
119	Probiotic microbes sustain youthful serum testosterone levels and testicular size in aging mice. <i>PLoS ONE</i> , 2014 , 9, e84877	3.7	77
118	Lymphoma caused by intestinal microbiota. 2014 , 11, 9038-49		15
117	Gut microbiota and the paradox of cancer immunotherapy. <i>Frontiers in Immunology</i> , 2014 , 5, 157	8.4	28

116	Intestinal microbiome and lymphoma development. 2014 , 20, 190-4		24
115	Rodent intestinal epithelial carcinogenesis: pathology and preclinical models. 2014 , 42, 148-61		14
114	Chronic inflammation and cytokines in the tumor microenvironment. 2014 , 2014, 149185		930
113	Urokinase-type plasminogen activator deficiency promotes neoplasmatogenesis in the colon of mice. 2014 , 7, 174-187.e5		18
112	Gastrointestinal malignancy and the microbiome. 2014 , 146, 1534-1546.e3		195
111	Animal models of gastrointestinal inflammation and cancer. <i>Life Sciences</i> , 2014 , 108, 1-6	6.8	10
110	Pathogenic properties of enterohepatic <i>Helicobacter</i> spp. isolated from rhesus macaques with intestinal adenocarcinoma. <i>Journal of Medical Microbiology</i> , 2014 , 63, 1004-1016	3.2	15
109	Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. 2014 , 22, 1018-28		133
108	Microbial Reprogramming Inhibits Western Diet-Associated Obesity. 2014 , 17-43		
107	Animal Models of IBD-Associated CRC and Colorectal Cancer Tumorigenesis. 2015 , 7, CMT.S18489		3
106	Relationship between intestinal microbiota and colorectal cancer. 2015 , 7, 233-40		24
105	Association between <i>Helicobacter</i> spp. infections and hepatobiliary malignancies: a review. <i>World Journal of Gastroenterology</i> , 2015 , 21, 1414-23	5.6	39
104	Gut bacteria and cancer. 2015 , 1856, 86-90		31
103	Immunology and Immunotherapy of Colorectal Cancer. 2015 , 217-236		2
102	<i>Helicobacter cinaedi</i> induced typhlocolitis in Rag-2-deficient mice. 2015 , 20, 146-55		6
101	Cholera-toxin suppresses carcinogenesis in a mouse model of inflammation-driven sporadic colon cancer. 2015 , 36, 280-90		25
100	Low infiltration of peritumoral regulatory T cells predicts worse outcome following resection of colorectal liver metastases. 2015 , 22, 180-6		31
99	Biology and Diseases of Mice. 2015 , 43-149		20

98	Tumor-Elicited Inflammation and Colorectal Cancer. 2015 , 128, 173-96		99
97	Akkermansia muciniphila and Helicobacter typhlonius modulate intestinal tumor development in mice. 2015 , 36, 1388-96		61
96	The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. <i>European Journal of Immunology</i> , 2015 , 45, 17-31	6.1	143
95	Beneficial bacteria inhibit cachexia. <i>Oncotarget</i> , 2016 , 7, 11803-16	3.3	62
94	Lamellipodin-Deficient Mice: A Model of Rectal Carcinoma. <i>PLoS ONE</i> , 2016 , 11, e0152940	3.7	3
93	The Prognostic Significance of FoxP3+ T Cells and CD8+ T Cells in Colorectal Carcinomas. 2016 , 35, 121-31		9
92	Loss of intestinal O-glycans promotes spontaneous duodenal tumors. 2016 , 311, G74-83		20
91	Regulatory T Cells and Cancer: A Two-Sided Story. 2016 , 45, 797-812		30
90	Role of the Microbiota in Colorectal Cancer: Updates on Microbial Associations and Therapeutic Implications. 2016 , 5, 279-288		36
89	Molecular Targets and Strategies in Cancer Prevention. 2016 ,		
88	Microbiota and Chronic Inflammation as Targets for Colorectal Cancer Prevention. 2016 , 21-35		1
87	Mouse models of intestinal inflammation and cancer. 2016 , 90, 2109-2130		12
86	Helicobacter saguini, a Novel Helicobacter Isolated from Cotton-Top Tamarins with Ulcerative Colitis, Has Proinflammatory Properties and Induces Typhlocolitis and Dysplasia in Gnotobiotic IL-10 ^{-/-} Mice. 2016 , 84, 2307-2316		15
85	Microbes and Cancer. 2017 , 35, 199-228		127
84	Insights into the role of the intestinal microbiota in colon cancer. 2017 , 10, 417-428		21
83	Interleukin-22 drives nitric oxide-dependent DNA damage and dysplasia in a murine model of colitis-associated cancer. 2017 , 10, 1504-1517		40
82	Enrichment of Human CCR6 Regulatory T Cells with Superior Suppressive Activity in Oral Cancer. 2017 , 199, 467-476		29
81	Regulatory T-cell heterogeneity and the cancer immune response. 2017 , 6, e154		77

80	Gut microbiota and colorectal cancer: insights into pathogenesis for novel therapeutic strategies. 2017 , 55, 872-880		5
79	A Large Polysaccharide Produced by <i>Helicobacter hepaticus</i> Induces an Anti-inflammatory Gene Signature in Macrophages. 2017 , 22, 733-745.e5		59
78	Gut microbiota modulate host immune cells in cancer development and growth. 2017 , 105, 28-34		18
77	Gastrointestinal microbiome and breast cancer: correlations, mechanisms and potential clinical implications. <i>Breast Cancer</i> , 2017 , 24, 220-228	3.4	57
76	The Clinicopathological and Prognostic Implications of FoxP3 Regulatory T Cells in Patients with Colorectal Cancer: A Meta-Analysis. <i>Frontiers in Physiology</i> , 2017 , 8, 950	4.6	22
75	Acquired haemophilia in cancer: A systematic and critical literature review. <i>Haemophilia</i> , 2018 , 24, 43-56	3.3	38
74	A catch-22: Interleukin-22 and cancer. <i>European Journal of Immunology</i> , 2018 , 48, 15-31	6.1	60
73	Oral Dysbiosis in Pancreatic Cancer and Liver Cirrhosis: A Review of the Literature. <i>Biomedicines</i> , 2018 , 6,	4.8	30
72	Microbiome and Diseases: Colorectal Cancer. 2018 , 231-249		2
71	Intestinal-Based Diseases and Peripheral Infection Risk Associated with Gut Dysbiosis: Therapeutic use of Pre- and Probiotics and Fecal Microbiota Transplantation. 2018 , 197-288		
70	Dysbiosis of the Microbiota: Therapeutic Strategies Utilizing Dietary Modification, Pro- and Prebiotics and Fecal Transplant Therapies in Promoting Normal Balance and Local GI Functions. 2018 , 381-419		2
69	Inflammation-induced DNA damage, mutations and cancer. <i>DNA Repair</i> , 2019 , 83, 102673	4.3	74
68	Nutrition, Immunity, and Cancer. 2019 , 209-281		1
67	Mice Deficient in Epithelial or Myeloid Cell I κ B Have Distinct Colonic Microbiomes and Increased Resistance to Infection. <i>Frontiers in Immunology</i> , 2019 , 10, 2062	8.4	2
66	Complex interactions between the microbiome and cancer immune therapy. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2019 , 56, 567-585	9.4	17
65	Relationship between intestinal microorganisms and T lymphocytes in colorectal cancer. <i>Future Oncology</i> , 2019 , 15, 1655-1666	3.6	7
64	Oral Mucosal Immunity and Microbiome. <i>Advances in Experimental Medicine and Biology</i> , 2019 ,	3.6	1
63	IL-17 inhibits CXCL9/10-mediated recruitment of CD8 cytotoxic T cells and regulatory T cells to colorectal tumors. 2019 , 7, 324		24

62	Obligate and facultative anaerobic bacteria in targeted cancer therapy: Current strategies and clinical applications. <i>Life Sciences</i> , 2020 , 261, 118296	6.8	8
61	GM-CSF Calibrates Macrophage Defense and Wound Healing Programs during Intestinal Infection and Inflammation. <i>Cell Reports</i> , 2020 , 32, 107857	10.6	25
60	Microbial Alterations and Risk Factors of Breast Cancer: Connections and Mechanistic Insights. <i>Cells</i> , 2020 , 9,	7.9	14
59	Paradoxical interaction between cancer and long-term postsepsis disorder: impairment of de novo carcinogenesis versus favoring the growth of established tumors. 2020 , 8,		2
58	Analysis of mutations in tumor and normal adjacent tissue via fluorescence detection. <i>Environmental and Molecular Mutagenesis</i> , 2021 , 62, 108-123	3.2	0
57	Breast and gut microbiome in health and cancer. <i>Genes and Diseases</i> , 2021 , 8, 581-589	6.6	11
56	Microbiome-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer.		1
55	Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020 , 11, 612202	8.4	22
54	is required for immune targeting of bacterial heat shock protein 60 and fatal colitis in mice. <i>Gut Microbes</i> , 2021 , 13, 1-20	8.8	3
53	Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8 T Cells. <i>Frontiers in Immunology</i> , 2021 , 12, 615089	8.4	0
52	It takes a village: microbiota, parainflammation, paligenosis and bystander effects in colorectal cancer initiation. <i>DMM Disease Models and Mechanisms</i> , 2021 , 14,	4.1	1
51	MTH1 as a target to alleviate T cell driven diseases by selective suppression of activated T cells. <i>Cell Death and Differentiation</i> , 2021 ,	12.7	0
50	Emerging Complexity in CD4T Lineage Programming and Its Implications in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2021 , 12, 694833	8.4	2
49	Helicobacter-based mouse models of digestive system carcinogenesis. <i>Methods in Molecular Biology</i> , 2009 , 511, 267-95	1.4	42
48	Inflammatory bowel disease: a model of chronic inflammation-induced cancer. <i>Methods in Molecular Biology</i> , 2009 , 511, 193-233	1.4	33
47	Helicobacter spp. in Experimental Models of Colitis. <i>Advances in Experimental Medicine and Biology</i> , 2019 , 1197, 97-105	3.6	1
46	Enterohepatic Helicobacter spp. in cats with non-haematopoietic intestinal carcinoma: a survey of 55 cases. <i>Journal of Medical Microbiology</i> , 2016 , 65, 814-820	3.2	6
45	Intestinal microbiota and colorectal cancer: changes in the intestinal microenvironment and their relation to the disease. <i>Journal of Medical Microbiology</i> , 2019 , 68, 1391-1407	3.2	15

44	Helicobacter pylori. 107-133		2
43	Pathogenic intestinal bacteria enhance prostate cancer development via systemic activation of immune cells in mice. <i>PLoS ONE</i> , 2013 , 8, e73933	3.7	45
42	Interferon- γ induces expression of MHC class II on intestinal epithelial cells and protects mice from colitis. <i>PLoS ONE</i> , 2014 , 9, e86844	3.7	70
41	CD4 ⁺ CD25 ^{hi} CD127 ^{low} regulatory T cells are increased in oral squamous cell carcinoma patients. <i>PLoS ONE</i> , 2014 , 9, e103975	3.7	41
40	Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development. <i>PLoS Pathogens</i> , 2017 , 13, e1006440	7.6	85
39	Keratin 8 reduces colonic permeability and maintains gut microbiota homeostasis, protecting against colitis and colitis-associated tumorigenesis. <i>Oncotarget</i> , 2017 , 8, 96774-96790	3.3	11
38	Gut bacteria require neutrophils to promote mammary tumorigenesis. <i>Oncotarget</i> , 2015 , 6, 9387-96	3.3	64
37	In Vivo Anti Cancer Potential of Pyrogallol in Murine Model of Colon Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019 , 20, 2645-2651	1.7	2
36	Increased presence of effector lymphocytes during Helicobacter hepaticus-induced colitis. <i>World Journal of Gastroenterology</i> , 2012 , 18, 1459-69	5.6	6
35	Immune reaction and colorectal cancer: friends or foes?. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12407-19	5.6	15
34	Impact of the immune system and immunotherapy in colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015 , 6, 208-23	2.8	98
33	Stem and immune cells in colorectal primary tumour: Number and function of subsets may diagnose metastasis. <i>World Journal of Immunology</i> , 2015 , 5, 68	0.5	1
32	Helicobacter hepaticus and Helicobacter bilis: proinflammatory modulators of enterohepatic disease. 2003 , 15-29		
31	EVIDENCE FOR THE EXISTENCE OF CANCER IMMUNOSURVEILLANCE. <i>Annals of Cancer Research and Therapy</i> , 2004 , 12, 9-32	0.2	
30	Intercurrent Infections in Genetically Engineered Mice.		
29	Host Interactions with Bacteria: From Entente Cordiale To Casus Belli 2013 , 281-305		
28	'Hygienic' lymphocytes convey increased cancer risk. <i>Journal of Analytical Oncology</i> , 2014 , 3, 113-121		4
27	Inflammation and Colorectal Cancer. 2015 , 211-256		

26	Multi-Omics Characterization of Inflammatory Bowel Disease-Induced Hyperplasia/Dysplasia in the / Mouse Model. <i>International Journal of Molecular Sciences</i> , 2020 , 22,	6.3	1
25	Immunology and immunotherapy in CRC. 2022 , 435-453		
24	Immunology and Immunotherapy of Colorectal Cancer. 2020 , 261-289		0
23	Helicobacter hepaticus as disease driver in a novel CD40-mediated model of colitis.		
22	Effects of Helicobacter infection on research: the case for eradication of Helicobacter from rodent research colonies. <i>Comparative Medicine</i> , 2009 , 59, 10-7	1.6	26
21	Resistance of Sprague-Dawley Rats to infection with Helicobacter pullorum. <i>Journal of the American Association for Laboratory Animal Science</i> , 2012 , 51, 803-7	1.3	5
20	Helicobacter hepaticus, a new pathogenic species of the Helicobacter genus: Similarities and differences with H. pylori. <i>Iranian Journal of Microbiology</i> , 2013 , 5, 185-94	0.9	7
19	Isolation of Helicobacter spp. from mice with rectal prolapses. <i>Comparative Medicine</i> , 2014 , 64, 171-8	1.6	15
18	Inflammatory cells' role in acetic acid-induced colitis. <i>Advanced Biomedical Research</i> , 2014 , 3, 193	1.2	7
17	Microbial-Driven Immunological Memory and Its Potential Role in Microbiome Editing for the Prevention of Colorectal Cancer. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 752304	5.9	0
16	Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer. <i>Immunity</i> , 2021 ,	32.3	6
15	Apoptosis triggered by cytolethal distending toxin B subunit of Helicobacter hepaticus is aggravated by autophagy inhibition in mouse hepatocytes.. <i>Biochemical and Biophysical Research Communications</i> , 2022 , 598, 40-46	3.4	
14	Metagenomic Analyses Reveal Distinct Gut Microbiota Signature for Predicting the Neoadjuvant Chemotherapy Responsiveness in Breast Cancer Patients.. <i>Frontiers in Oncology</i> , 2022 , 12, 865121	5.3	0
13	Quantitative Proteogenomic Characterization of Inflamed Murine Colon Tissue Using an Integrated Discovery, Verification, and Validation Proteogenomic Workflow.. <i>Proteomes</i> , 2022 , 10,	4.6	0
12	Image_1.jpg. 2019 ,		
11	Image_2.jpg. 2019 ,		
10	Image_3.jpg. 2019 ,		
9	Impact of the Tumor Microenvironment for Esophageal Tumor Development-An Opportunity for Prevention?. <i>Cancers</i> , 2022 , 14,	6.6	

8	Dynamics of Changes in the Gut Microbiota of Healthy Mice Fed with Lactic Acid Bacteria and Bifidobacteria. <i>Microorganisms</i> , 2022 , 10, 1020	4.9	4
7	Emerging role of human microbiome in cancer development and response to therapy: special focus on intestinal microflora. <i>Journal of Translational Medicine</i> , 2022 , 20,	8.5	5
6	Low-dose interleukin-2 shapes a tolerogenic gut microbiota that improves autoimmunity and gut inflammation.		1
5	Attenuation of regulatory T cell function by type I IFN signaling in an MDA5 gain-of-function mutant mouse model. 2022 , 629, 171-175		0
4	Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics. 2022 , 8, e10450		0
3	Modulating Microbiota as a New Strategy for Breast Cancer Prevention and Treatment. 2022 , 10, 1727		1
2	Applying multi-omics toward tumor microbiome research.		0
1	Human microbiomes in cancer development and therapy. 2023 , 4,		0